| Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations M Dankner, AAN Rose, S Rajkumar, PM Siegel, IR Watson Oncogene 37 (24), 3183-3199, 2018 | 488 | 2018 |
| Spatially mapping the immune landscape of melanoma using imaging mass cytometry D Moldoveanu, LA Ramsay, M Lajoie, L Anderson-Trocme, M Lingrand, ... Science immunology 7 (70), eabi5072, 2022 | 93 | 2022 |
| Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies S Rajkumar, IR Watson British journal of cancer 115 (2), 145-155, 2016 | 84 | 2016 |
| Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanomas M Dankner, M Lajoie, D Moldoveanu, TT Nguyen, P Savage, S Rajkumar, ... Clinical Cancer Research 24 (24), 6483-6494, 2018 | 71 | 2018 |
| Melanomas with concurrent BRAF non-p. V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy S Rajkumar, D Berry, KA Heney, C Strong, LA Ramsay, M Lajoie, ... Cell Reports 39 (1), 2022 | 21 | 2022 |
| Reprogramming of nucleotide metabolism mediates synergy between epigenetic therapy and MAP kinase inhibition T Shorstova, J Su, T Zhao, M Dahabieh, M Leibovitch, ... Molecular Cancer Therapeutics 20 (1), 64-75, 2021 | 9 | 2021 |
| Investigation of the co-operativity of mutations in the mitogen-activated protein kinase (MAPK) pathway in cutaneous melanomas S Rajkumar McGill University (Canada), 2022 | | 2022 |
| Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM). M Dankner, M Lajoie, D Moldoveanu, S Rajkumar, TT Nguyen, P Savage, ... Journal of Clinical Oncology 36 (15_suppl), 12093-12093, 2018 | | 2018 |
| Abstract B056: Non-V600 BRAF mutations in melanoma: actionable targets for rational drug combinations AAN Rose, M Dankner, S Rajkumar, IR Watson, K Petrecca, C Mihalcioiu, ... Molecular Cancer Therapeutics 17 (1_Supplement), B056-B056, 2018 | | 2018 |
